TMO
Thermo Fisher Scientific Inc. NYSE$469.21
Mkt Cap $176.9B
52w Low $385.46
32.4% of range
52w High $643.99
50d MA $497.05
200d MA $526.19
P/E (TTM)
26.4x
EV/EBITDA
21.7x
P/B
3.3x
Debt/Equity
0.8x
ROE
12.6%
P/FCF
34.6x
RSI (14)
—
ATR (14)
—
Beta
0.97
50d MA
$497.05
200d MA
$526.19
Avg Volume
2.2M
About
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines,…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 5.25 | 5.44 | +3.6% | 466.70 | +0.5% | +0.6% | +0.3% | +0.8% | -0.1% | +2.6% | — | — |
| Jan 29, 2026 | AMC | 6.45 | 6.57 | +1.9% | 592.16 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% | -14.1% | — |
| Oct 22, 2025 | AMC | 5.50 | 5.79 | +5.3% | 567.20 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% | +3.6% | — |
| Jul 23, 2025 | AMC | 5.23 | 5.36 | +2.5% | 466.71 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% | +7.1% | — |
| Apr 23, 2025 | AMC | 5.10 | 5.15 | +1.0% | 431.64 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% | -8.8% | — |
| Jan 30, 2025 | AMC | 5.94 | 6.10 | +2.7% | 606.74 | -1.1% | -1.5% | -2.1% | -4.3% | -4.0% | -5.6% | -13.7% | — |
| Oct 23, 2024 | AMC | 5.25 | 5.28 | +0.6% | 576.49 | -0.7% | -3.3% | -3.8% | -4.2% | -5.0% | -4.5% | -11.0% | — |
| Jul 24, 2024 | AMC | 5.12 | 5.37 | +4.9% | 574.73 | +0.2% | +3.4% | +5.6% | +5.1% | +7.0% | +6.7% | +5.5% | — |
| Apr 24, 2024 | AMC | 4.71 | 5.11 | +8.5% | 577.39 | +0.0% | -1.0% | -0.7% | -0.1% | -1.5% | -0.4% | +1.2% | — |
| Jan 31, 2024 | AMC | 5.64 | 5.67 | +0.5% | 538.98 | +0.6% | +2.5% | +2.4% | +2.3% | +4.0% | +2.5% | +6.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Stifel | Maintains | Buy → Buy | — | $466.70 | $469.15 | +0.5% | +0.6% | +0.3% | +0.8% | -0.1% | +2.6% |
| Apr 24 | Baird | Maintains | Outperform → Outperform | — | $466.70 | $469.15 | +0.5% | +0.6% | +0.3% | +0.8% | -0.1% | +2.6% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $514.23 | $516.34 | +0.4% | +2.5% | +3.4% | +0.3% | +2.4% | +2.3% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $491.46 | $492.00 | +0.1% | -0.7% | -0.4% | +2.4% | +1.8% | +0.9% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $592.16 | $581.73 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% |
| Jan 30 | TD Cowen | Maintains | Buy → Buy | — | $592.16 | $581.73 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% |
| Jan 30 | Citigroup | Maintains | Buy → Buy | — | $592.16 | $581.73 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% |
| Jan 9 | Stifel | Maintains | Buy → Buy | — | $606.50 | $608.61 | +0.3% | +2.0% | +1.5% | +0.1% | +2.5% | +3.0% |
| Jan 7 | TD Cowen | Maintains | Buy → Buy | — | $620.72 | $618.70 | -0.3% | -0.6% | -2.3% | -0.3% | -0.8% | -2.2% |
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $572.28 | $574.23 | +0.3% | +0.6% | -0.4% | -1.7% | -1.7% | -0.8% |
Recent Filings
8-K
Thermo Fisher Scientific, Inc. -- 8-K Filing
Thermo Fisher Scientific reported first quarter 2026 earnings results, with contact information provided for investor inquiries regarding the company's financial performance.
Apr 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A carefully negotiated executive departure with strict confidentiality provisions suggests potential internal conflict or performance issues, warranting investor scrutiny of management stability and upcoming leadership announcements.
Apr 1
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced diagnostics executive joining PostiveID (PSTV) as a leader strengthens management credibility and operational capability, potentially improving execution in the diagnostics sector.
Mar 26
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Thermo Fisher's $8.9 billion acquisition of Clario expands its clinical trial capabilities and diversifies revenue streams, but investors should monitor integration execution and earnout obligations that could increase total costs.
Mar 24
8-K
Unknown — 8-K Filing
Aurinia's executive leadership transition with a new COO appointment signals operational restructuring; the CEO's voluntary compensation waiver suggests confidence in turnaround strategy, potentially reducing near-term cash burn.
Mar 23
8-K · 1.01
! Medium
Thermo Fisher Scientific, Inc. -- 8-K 1.01: Financing / Debt Agreement
Thermo Fisher Scientific secured a financing arrangement with Deutsche Bank Securities, potentially providing capital access for operations, acquisitions, or debt refinancing activities.
Feb 12
Data updated apr 27, 2026 5:05am
· Source: massive.com